{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:30:43Z","timestamp":1765279843033,"version":"3.38.0"},"reference-count":103,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Womens Health (Lond Engl)"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:p> The amount of the largest diameter of visible residual tumor after cytoreductive surgery remains one of the strongest prognostic factors In advanced ovarian cancer. The Implementation of a more aggressive surgical approach to Increase the proportion of patients without visible residual tumor Is, therefore, a rational concept. Thus, the surgical management of advanced ovarian, primary peritoneal and fallopian tube cancers now Incorporates more comprehensive surgical procedures. However, these more extensive surgical procedures are associated with an Increased risk of morbidity, which may have a negative Impact on the oncologic outcome. In addition, It Is unclear whether all patients benefit from a comprehensive surgical Intervention In the same way or If there are patients whose disease course will not be Influenced by this approach. The methodologic analysis of surgical effectiveness Is complex and controversial owing to a lack of prospective surgical trials. This review acknowledges controversies and alms to discuss novel developments In the field of cytoreductive surgery for patients with ovarian, primary peritoneal and fallopian tube cancers. The focus of the review Is to discuss the role of surgery at Initial diagnosis. The role of secondary and tertiary surgery In the recurrent setting Is beyond the scope of this review. <\/jats:p>","DOI":"10.2217\/whe.14.4","type":"journal-article","created":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T10:04:54Z","timestamp":1394186694000},"page":"179-190","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Cytoreductive Surgery for Advanced Ovarian Cancer"],"prefix":"10.1177","volume":"10","author":[{"given":"Martin","family":"P\u00f6lcher","sequence":"first","affiliation":[{"name":"Red Cross Women's Hospital Munich, Department of Gynecologic Oncology & Minimally-Invasive Surgery, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis S","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"bibr1a-WHE.14.4","unstructured":"Papers of special note have been highlighted as:"},{"key":"bibr2a-WHE.14.4","unstructured":"of interest"},{"key":"bibr3a-WHE.14.4","unstructured":"of considerable interest"},{"key":"bibr1-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20138"},{"key":"bibr2-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(06)60033-7"},{"key":"bibr3-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61157-0"},{"key":"bibr4-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052985"},{"key":"bibr8a-WHE.14.4","unstructured":"These findings prompted the National Cancer Institute (MD, USA) to make a clinical anouncement in 2006. Based on the results of these randomized Phase III trials, a combination of intravenous and intraperitoneal administration of chemotherapy conveys a significant survival benefit among women with optimally debulked epithelial ovarian cancer compared with intravenous administration alone."},{"key":"bibr5-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"bibr6-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"bibr7-WHE.14.4","doi-asserted-by":"crossref","unstructured":"Du Bois A, Floquet A, Kim JW,  Randomized, double-blind, Phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international intergroup trial (AGO-OVAR16) J. Clin. Oncol. (Suppl.), Abstract LBA5503 (2013).","DOI":"10.1200\/jco.2013.31.18_suppl.lba5503"},{"key":"bibr8-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9626"},{"volume-title":"Tumors of the Female Pelvic Organs.","year":"1934","author":"Meigs JV","key":"bibr9-WHE.14.4"},{"key":"bibr10-WHE.14.4","first-page":"101","volume":"42","author":"Griffiths CT","year":"1975","journal-title":"Natl Cancer Inst. Monogr."},{"key":"bibr11-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(94)70090-7"},{"key":"bibr12-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000192407.04428.bb"},{"key":"bibr13-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.03.051"},{"key":"bibr18a-WHE.14.4","unstructured":"This study is important because it shows that, among those patients with larger residual disease, size does not affect prognosis appreciably."},{"issue":"6","key":"bibr14-WHE.14.4","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"Du Bois A","year":"2009","journal-title":"Cancer"},{"key":"bibr15-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2517"},{"key":"bibr16-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1248"},{"key":"bibr22a-WHE.14.4","unstructured":"This meta-analysis shows that maximal cytoreduction was one of the most powerful determinants of cohort survival among patients with stage III or IV ovarian carcinoma."},{"key":"bibr17-WHE.14.4","first-page":"CD007565","volume":"8","author":"Elattar A","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"bibr18-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.03.018"},{"key":"bibr19-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6312"},{"key":"bibr20-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.10.001"},{"key":"bibr21-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4890"},{"key":"bibr22-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.08.014"},{"key":"bibr23-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.02.014"},{"key":"bibr24-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.07.032"},{"key":"bibr25-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8992"},{"key":"bibr26-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.5926"},{"key":"bibr27-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.01.029"},{"key":"bibr28-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.11.022"},{"key":"bibr29-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.05.023"},{"key":"bibr30-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.08.027"},{"key":"bibr31-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.7800"},{"key":"bibr32-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO;2-A"},{"key":"bibr33-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20376"},{"key":"bibr34-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.2003.13019.x"},{"key":"bibr35-WHE.14.4","doi-asserted-by":"crossref","unstructured":"Kehoe SM, Hook J, Nankivell M,  Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. Presented at: 2013 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, May 31\u2013June 4 2013.","DOI":"10.1200\/jco.2013.31.15_suppl.5500"},{"key":"bibr36-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908806"},{"key":"bibr43a-WHE.14.4","unstructured":"This is the first randomized trial exploring the role of neoadjuvant chemotherapy in patients with advanced ovarian cancer. The trial demonstrated no difference in progress ion-free and overall survival between primary surgery versus neoadjuvant chemotherapy."},{"key":"bibr37-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0787-8"},{"key":"bibr38-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2008.01.005"},{"key":"bibr39-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31827de6b9"},{"key":"bibr40-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31826a3559"},{"key":"bibr41-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.05.031"},{"key":"bibr42-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.12.423"},{"key":"bibr43-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181c10c04"},{"key":"bibr44-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31822a6d56"},{"key":"bibr45-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.08.027"},{"key":"bibr46-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31826981de"},{"key":"bibr47-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.03.079"},{"key":"bibr48-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2006.06.019"},{"key":"bibr49-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.04.030"},{"key":"bibr50-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2011.09.003"},{"key":"bibr51-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2006.06.027"},{"key":"bibr52-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(03)00478-2"},{"key":"bibr53-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.6135"},{"key":"bibr54-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.01006.x"},{"key":"bibr55-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.02.012"},{"key":"bibr56-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2010.01.011"},{"key":"bibr57-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.07.014"},{"key":"bibr58-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31822f65c3"},{"key":"bibr59-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.11.023"},{"key":"bibr60-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2010.10.004"},{"key":"bibr61-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.03.028"},{"key":"bibr62-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.08.036"},{"key":"bibr63-WHE.14.4","unstructured":"Kehoe SM, Abu-Rustum NR, Sonoda Y. Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian cancer. Presented at: the 38th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncologists. San Diego, CA, USA, 3\u20137 March 2007."},{"key":"bibr64-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.12.328"},{"key":"bibr65-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.01.024"},{"key":"bibr66-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.12.350"},{"key":"bibr67-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6313"},{"key":"bibr68-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1953"},{"key":"bibr69-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.04.027"},{"issue":"3","key":"bibr70-WHE.14.4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/IGC.0b013e3181d09fd6","volume":"20","author":"Chi DS","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"bibr71-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.10.010"},{"issue":"3","key":"bibr72-WHE.14.4","first-page":"1","volume":"12","author":"Dedrick RL","year":"1985","journal-title":"Semin. Oncol."},{"key":"bibr73-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1007\/BF00253116"},{"key":"bibr74-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1097\/00002480-198904000-00016"},{"key":"bibr75-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686048"},{"key":"bibr76-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(89)90359-3"},{"key":"bibr77-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685503"},{"key":"bibr78-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199612263352603"},{"key":"bibr86a-WHE.14.4","unstructured":"This study revealed a statistically significant improvement in overall survival associated with regional delivery of cisplatin."},{"issue":"4","key":"bibr79-WHE.14.4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman M","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"bibr80-WHE.14.4","unstructured":"National Cancer Institute. Intraperitoneal Therapy for Ovarian Cancer (2006). www.cancer.gov\/clinicaltrials\/conducting\/developments\/ipchemo-digest\/Page1"},{"key":"bibr81-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0376"},{"key":"bibr90a-WHE.14.4","unstructured":"Despite the National Cancer Institute announcement, the European Organization for Research and Treatment of Cancer (Brussels, Belgium) and the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie-Germany (Munich, Germany) are unconvinced by available data, and still consider this treatment experimental, mainly because of the higher toxicity rates and the high rate of discontinuation."},{"key":"bibr82-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90389-U"},{"key":"bibr83-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90472-9"},{"key":"bibr84-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.45"},{"key":"bibr85-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-007-0313-z"},{"key":"bibr86-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-2-21"},{"key":"bibr87-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23553"},{"key":"bibr88-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20676"},{"key":"bibr89-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.071"},{"key":"bibr90-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-9966-2"},{"key":"bibr91-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.187"},{"key":"bibr92-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1631-5"},{"key":"bibr93-WHE.14.4","unstructured":"ClincialTrials.gov. A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers. http:\/\/clinicaltrials.gov\/show\/NCT01659554"},{"key":"bibr94-WHE.14.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2009.01.006"}],"container-title":["Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/WHE.14.4","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2217\/WHE.14.4","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/WHE.14.4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T19:03:38Z","timestamp":1741633418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2217\/WHE.14.4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.2217\/WHE.14.4"],"URL":"https:\/\/doi.org\/10.2217\/whe.14.4","relation":{},"ISSN":["1745-5057","1745-5065"],"issn-type":[{"type":"print","value":"1745-5057"},{"type":"electronic","value":"1745-5065"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}